Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

Quarterly Focus on Genitourinary Cancer: highlights in prostate cancer (part 2)

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.

In this third episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Bladder Cancer from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications.

The expert panel consist of:
Niven Mehra, MD, PhD – medical oncologist, Radboudumc, Nijmegen
Andre Bergman, MD, PhD – medical oncologist, Netherlands Cancer Institute, Amsterdam
Prof. Theo de Reijke, MD - urologist, Amsterdam UMC, Amsterdam


Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer (LATITUDE)
N Engl J M, July 27, 2017

Speaker: Karim Fizazi, MD, PhD - medical oncologist, Gustave Roussy Institute, Villejuif, France

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
The Lancet, Oct 21, 2018

Speaker: Prof. Nicholas James, PhD - medical oncologist, University of Birmingham, UK

  • Invited speakers

  • Niven Mehra, MD, PhD

    medical oncologist

    Radboudumc, Nijmegen

  • Andre Bergman, MD, PhD

    medical oncologist

    NKI-AvL, Amsterdam

  • Prof. Theo de Reijke, MD


    Amsterdam UMC, Amsterdam

  • Karim Fizazi, MD, PhD

    medical oncologist

    Institut Gustave Roussy, Villejuif, France

  • Prof. Nicholas James, MD, PhD

    medical oncologist

    University Hospitals Birmingham NHS Trust, Birmingham, UK

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congresnieuws 18/02/2017

​ASCO GU 2017: RT versus surgery in Gleason 9-10 Pca

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Amar Kishan Poster: A7 - Radiotherapy versus radical prostatectomy for Gleason score 9-10 prostate adenocarcinoma: A multi-institutional comparative analysis of 1001 patients treated in the modern era

Congresnieuws 12/03/2015

Oncology News Program at Genitourinary Cancers Symposium 2015

The 2015 Genitourinary Cancers Symposium was held in Orlando from February 26th to 28th. In a multidisciplinary Oncology News Program Dutch and Belgian experts will discuss new important data, presented at this congress. In the first part of this Oncology News Program Dr. Thierry Gil, Prof. Jeroen van Moorselaar and Dr. Fons van den Bergh talk about the role of Androgen Deprivation Therapy in early and intermediate risk prostate cancer, dose escalation in Radiotherapy, Stereotactic Body Radiotherapy and possible predictive markers like Slco2B1 and androgen receptor splice variant 7. The second part covers the following topics on prostate cancer: Active Surveillance in early stage prostate cancer, Brachytherapy versus External Beam Radiation Therapy, active immunotherapy and check point inhibitors and one of the highlights of this congress, the GETUG-15 trial. These data are discussed by Prof. Winald Gerritsen, Prof. Gert De Meerleer and Prof. Thierry Roumeguère. The panel for the last part of this Oncology News Program consists of Prof. Gerritsen, Prof. van Moorselaar and Prof. Roumeguère. The experts discuss important new data on GU-non prostate cancer: organ sparing versus radical cystectomy, (neo)adjuvant chemotherapy in bladder cancer, the role of profiling urothelial cancer, anti-PDL1 and Pazopanib in combination with Paclitaxel in refractory urothelial cancer. Presented by dr. Ayan Panja.

Congresnieuws 18/02/2017

ASCO GU 2017: Discussion program on prostate and bladder cancer

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. An international multidisciplinary panel discussed a selection of topics and new data on prostate and bladder cancer. During a live connection, questions were submitted by participants of the ASCO Direct GU Virtual meetings in 7 different countries (Austria, Belgium, Brazil, Germany, Netherlands, United Arabic Emirates and Switzerland) Topics: Active surveillance in localized prostate cancer Impact of ProtecT trial results Value of imaging, genomics, and genetics for active surveillance High-risk prostate cancer, definition and therapeutic controversies Value of chemoradiation for bladder cancer Molecular predictors and response to neoadjuvant chemotherapy in bladder cancer Speakers: Prof. Bertrand Tombal MD PhD, urologist, Université catholique de Louvain, Cliniques universitaires Saint-Luc, Brussels, Belgium Prof. Robert Bristow MD PhD, radiation oncologist, Princess Margaret Hospital, Toronto, Canada Prof. Thomas Bauernhofer MD, medical oncologist, University Clinic for Internal Medicine Karl-Franzens University, Graz, Austria Neil Shore MD, urologist, Atlantic Urology Clinic, Myrtle Beach, USA Moderator: Catherine Hood PhD  

Congresnieuws 18/02/2017

ASCO GU 2017: Genomics of radioresistant Pca

A selection of posters from the 2017 Genitourinary Cancers Symposium is highlighted in a series of interviews. Speaker: Melvin Chua Poster: A26 - Genomic architecture of radioresistant prostate cancer

Congresnieuws 09/01/2016

2016 GU Cancers Symposium News Program

Prof. Anthony D´Amico (Dana Faber & Harvard Cancer Institute, USA) and Prof. Nick James (Warwick Medical School, UK) discuss the highlights of the 2016 Genitourinary Cancers Symposium which took place in San Francisco from the 7th – 9th January 2016. Topics include a.o.: standard versus hypofractionated radiotherapy in prostate cancer (abstract 1 & 2) Anti Androgen Therapy after radical prostatectomy (abstract 3) update of the STAMPEDE trial (celecoxinib and zoledronic acida arms) (abstract 162) the role of circulating cell free DNA in profiling urothelial carcinoma (abstract 163) adjuvant radiation vs. chemo-radiation vs. chemotherapy alone after radical cystectomy for locally advanced bladder cancer (abstract 356)

Congresnieuws 12/12/2018

EMUC 2018: Take home messages

Dr. Laurence Albiges, medical oncologist at the Institut Gustave Roussy (France), shares with us her take home messages of EMUC 2018, several of which might have practice changing potential. 

Congresnieuws 13/12/2018

EMUC 2018: STAMPEDE trial

Prof. Nicholas James, oncologist at the University Hospitals Birmingham NHS Trust (UK), talks us through the new results of the STAMPEDE trial. Do the results of abiraterone differ in patients with high risk metastatic prostate cancer as compared to patients in the low risk category? And is there any benefit of adding radiotherapy to systemic therapy?

Congresnieuws 13/12/2018

EMUC 2018: Highlights

Prof. Alberto Briganti, professor in the urology at the IRCCS Ospedale San Raffaele in Italy, is a member of the EMUC scientific committee on behalf of the EAU. He shares with us his personal highlights of the EMUC 2018, among which are the STAMPEDE and HORRAD trials and new radiological developments.